Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Concomitant anti-CGRP and immunomodulatory treatments in patients with migraine, towards integrated management strategies

  • García-Castillo, María Clara
  • Sierra Mencia, Álvaro|||0000-0002-0022-6064
  • Caronna, Edoardo|||0000-0001-5525-0267
  • Toledo-Alfocea, Daniel|||0000-0003-3651-1614
  • Jaimes, Alex|||0000-0002-0890-9484
  • Urtiaga, Saray
  • Casas-Limón, Javier|||0000-0002-7353-4084
  • Muñoz-Vendrell, Albert|||0000-0001-8221-865X
  • Santos Lasaosa, Sonia|||0000-0002-4141-7705
  • García Martín, Valvanuz
  • Martín Ávila, Guillermo
  • Polanco Fernández, Marcos
  • Villar-Martínez, Maria Dolores|||0000-0003-3920-0176
  • Trevino-Peinado, Cristina|||0000-0001-8711-4884
  • Rubio-Flores, Laura|||0000-0001-5570-8055
  • Sánchez-Soblechero, Antonio|||0000-0002-7098-8494
  • Portocarrero Sánchez, Leonardo
  • Luque-Buzo, Elisa|||0000-0002-7983-9268
  • Lozano Ros, Alberto|||0000-0002-5186-8657
  • Gago-Veiga, Ana Beatriz|||0000-0002-0038-3406
  • Díaz de Terán, Javier|||0000-0003-0064-6269
  • Recio García, Andrea
  • Canales Rodríguez, Javiera
  • Gómez García, Andrea
  • González Salaices, Marta
  • Campoy Diaz, Sergio|||0000-0002-8135-4139
  • Mínguez-Olaondo, Ane|||0000-0002-7742-3920
  • Maniataki, Stefania
  • González-Quintanilla, Vicente|||0000-0003-0902-3906
  • Porta-Etessam, Jesús|||0000-0002-7034-682X
  • Cuadrado, María Luz|||0000-0001-8246-3743
  • Guerrero Peral, Ángel Luis|||0000-0001-7493-6002
  • Pozo-Rosich, Patricia|||0000-0003-0796-4702
  • Rodríguez-Vico, Jaime|||0000-0001-9360-5444
  • Huerta, Mariano|||0000-0003-0181-5335
  • Pascual Gómez, Julio|||0000-0002-3189-7573
  • Goadsby, Peter J.|||0000-0003-3260-5904
  • Gonzalez-Martinez, Alicia|||0000-0002-1228-1503
Preclinical evidence supports the immunoregulatory role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology. The increasing use of anti-CGRP therapies in patients with migraine and other comorbidities raises the question whether the potential use of anti-CGRP monoclonal antibodies (CGRP-mAbs) therapies in combination with other immunological therapies is effective and safe. This multicenter study included patients with migraine receiving CGRP-mAbs combined with immunosuppressive and immunomodulatory treatments. Clinical and demographic data, treatment history, laboratory markers and treatment-emergent adverse events (TEAEs) were analyzed. Effectiveness outcomes included the change in monthly migraine days (MMD) and monthly headache days (MHD) at 3, 6, 9 and 12 months, alongside the.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Optimizing Chronic Migraine Care: The Impact of Advanced Practice Nurse Involvement in OnabotulinumtoxinA Administration

  • Gine-Cipres, Eulalia
  • Gallardo López, Víctor J.
  • TORRES-FERRUS, MARTA
  • Alpuente Ruiz, Alicia
  • Caronna, Edoardo
  • Gómez Dabó, Laura
  • Pozo-Rosich, Patricia
Advanced practice nursing; Botulinum toxin type A; Headache, Infermeria de pràctica avançada; Toxina botulínica tipus A; Mal de cap, Enfermería de práctica avanzada; Toxina botulínica tipo A; Dolor de cabeza, Background: Chronic migraine is a disabling and prevalent neurological disease that significantly impacts patients' quality of life. OnabotulinumtoxinA (OnabotA) is a safe and effective chronic migraine preventive treatment. The objective was to evaluate adherence to the recommended time interval between consecutive OnabotA injections according to the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) protocol, and to analyze changes in the interval adherence before and after the introduction of an Advanced Practice Nurse (APN) in a specialized Headache Unit of a tertiary hospital. Methods: This was a retrospective study performed in a Spanish specialized Headache Clinic. Patients diagnosed with chronic migraine and treated with OnabotA following the PREEMPT protocol were included, before and after the introduction of APNs. Treatment was considered interval-compliant if the injection interval ranged from 75 to 105 days. The data collected included three 18-month periods. Statistical analyses examined differences across periods using R-Studio. Results: A total of 2991 participants were included, of whom 83.8% (2507/2991) were women, with a median age [interquartile range (IQR)] of 48.0 [40.0–57.0] years old. A statistically significant association between the introduction of the APN and improved adherence to the PREEMPT protocol was observed over time (Z = –19.60, p < 0.001). Adherence rates increased from 52.1% in P1 to 76.1% in both P2 and P3. The median time between visits decreased from 105 days in P1 to 96 days in P2, with a slight increase to 98 days in P3. Conclusion: The involvement of advanced practice nurses in OnabotA administration decreased the time interval between infiltrations and improved adherence to the PREEMPT protocol. These findings highlight the APN's role in optimizing patient care.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Neck pain in migraine: A narrative review and steps to correct evaluation and treatment

  • Rees, Tayla
  • Doukhi, Diana
  • Wang, Victor S
  • Balcerbula, Anita
  • Bravo, Michelle
  • fathi, haniyeh
  • Caronna, Edoardo
  • Pozo-Rosich, Patricia
Evaluation; Migraine; Neck pain, Avaluació; Migranya; Dolor cervical, Evaluación; Migraña; Dolor cervical, Background Neck pain is common in migraine patients, occurring during all migraine phases and between attacks. It can be a migraine symptom, trigger or a coexisting condition, and is associated with greater disability and poorer treatment response. There is evidence that neck pain associated with headaches can be frequently incorrectly diagnosed as a cervical disorder rather than migraine, resulting in a lack of appropriate treatment. Accurately assessing the connection between neck pain and migraine is crucial for effective treatment. Methods This narrative review aims to summarise existing research on the role and contribution of neck pain in migraine, both as a symptom and a trigger, and outlines future research needed to deepen our understanding of this relationship. It also proposes a structured approach for assessing neck pain in migraine and a treatment algorithm, offering guidance for clinical evaluation and treatment. For this purpose, a comprehensive narrative review was conducted using PubMed, covering preclinical, clinical, neurophysiological and imaging evidence on migraine and neck pain. Results Migraine patients frequently exhibit cervical dysfunction, tenderness and altered posture, with overlapping neuroanatomical pathways of the neck and trigeminal systems, suggesting shared mechanisms of nociception and migraine initiation. Clinical assessment involves a thorough history, physical exam and exclusion of secondary causes. Standard migraine therapies, such as amitriptyline and onabotulinumtoxinA, may help reduce neck pain and non-pharmacological treatments, such as physical therapy, acupuncture and behavioural strategies, show some promise. However, evidence on neck pain relief is limited. Conclusions Accurately distinguishing whether neck pain is a symptom, trigger or comorbid condition in migraine is essential for guiding effective treatment strategies. Both pharmacological and non-pharmacological approaches may help manage migraine-associated neck pain. However, few studies have assessed the effects of acute or preventive migraine therapies, particularly calcitonin gene-related peptide-targeted treatments, on neck pain, highlighting a significant gap in our current knowledge. Future research should evaluate the effectiveness of these therapies on neck pain, both alone and in combination with non-pharmacological interventions., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: TAR acknowledges receipt of the International Headache Society Fellowship from the International Headache Society. EC’s salary has been partially funded by Río Hortega grant Acción Estratégica en Salud 2017–2020 from Instituto de Salud Carlos III (CM20/00217) and Juan Rodés fellowship, Subprograma Estatal de Incorporación de la Acción Estratégica en Salud 2023 (JR23/00065).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Early treatment in migraine – A call to shift prevention from attacks to disease progression: A position statement from the International Headache Society

  • Özge, Aynur
  • Pozo-Rosich, Patricia
  • Caronna, Edoardo
  • Sacco, Simona
  • Peres, Mario F P
  • Ashina, Sait
Anti-CGRP therapies; Migraine preventive treatment; Preventive treatment, Terapias anti-CGRP; Tratamiento preventivo de la migraña; Tratamiento preventivo, Teràpies anti-CGRP; Tractament preventiu de la migranya; Tractament preventiu, Migraine is one of the most disabling diseases worldwide, especially when it transforms into chronic migraine, which is often associated with medication overuse and can become resistant or even refractory to treatments. Molecular, neuroimaging and neurophysiological changes have been described in chronic migraine, some of which might not be fully reversible with preventive treatment. For these reasons, we should aim to prevent this transition, and initiate preventive treatment before disease becomes refractory and burden increases. Preventive migraine treatments are often delayed because of access to care, stigma leading to undertreatment and patients' reluctance as a result of fear of side effects and, in some cases, fear of being labeled as chronically ill. With the availability of effective and well-tolerated preventive treatments, we must shift our mindset and take advantage of new opportunities to initiate preventive treatment earlier. In this International Headache Society position statement, we propose a migraine preventive strategy under the idea of shifting from reactive treatment once disability is established (prevention of attacks), to proactive, individualized prevention initiated early with safe, effective and tolerable therapies (prevention of disease progression). This approach is based on 1) promoting the early initiation of effective and tolerable preventive therapies, starting from two to four monthly migraine days in line with the majority of current guidelines and recommendations and 2) fostering longitudinal studies to gather more evidence on the potential benefit of early prevention, with the final goal of improving patient outcomes, promoting excellent migraine care, enhancing individual and social well-being, and, ultimately, preventing migraine progression and preserving brain health., EC has received honoraria from Novartis, Chiesi, Lundbeck, MedScape, Lilly, TEVA, Organon and Dr Reddy's; his salary has been partially funded by Río Hortega grant Acción Estratégica en Salud 2017–2020 from Instituto de Salud Carlos III (CM20/00217) and Juan Rodés fellowship, Subprograma Estatal de Incorporación de la Acción Estratégica en Salud 2023 (JR23/00065). He is a junior editor for Cephalalgia.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Early treatment in migraine – A call to shift prevention from attacks to disease progression: A position statement from the International Headache Society

  • Özge, Aynur
  • Pozo-Rosich, Patricia
  • Caronna, Edoardo
  • Sacco, Simona
  • Peres, Mario F P
  • Ashina, Sait
Anti-CGRP therapies; Migraine preventive treatment; Preventive treatment, Terapias anti-CGRP; Tratamiento preventivo de la migraña; Tratamiento preventivo, Teràpies anti-CGRP; Tractament preventiu de la migranya; Tractament preventiu, Migraine is one of the most disabling diseases worldwide, especially when it transforms into chronic migraine, which is often associated with medication overuse and can become resistant or even refractory to treatments. Molecular, neuroimaging and neurophysiological changes have been described in chronic migraine, some of which might not be fully reversible with preventive treatment. For these reasons, we should aim to prevent this transition, and initiate preventive treatment before disease becomes refractory and burden increases. Preventive migraine treatments are often delayed because of access to care, stigma leading to undertreatment and patients' reluctance as a result of fear of side effects and, in some cases, fear of being labeled as chronically ill. With the availability of effective and well-tolerated preventive treatments, we must shift our mindset and take advantage of new opportunities to initiate preventive treatment earlier. In this International Headache Society position statement, we propose a migraine preventive strategy under the idea of shifting from reactive treatment once disability is established (prevention of attacks), to proactive, individualized prevention initiated early with safe, effective and tolerable therapies (prevention of disease progression). This approach is based on 1) promoting the early initiation of effective and tolerable preventive therapies, starting from two to four monthly migraine days in line with the majority of current guidelines and recommendations and 2) fostering longitudinal studies to gather more evidence on the potential benefit of early prevention, with the final goal of improving patient outcomes, promoting excellent migraine care, enhancing individual and social well-being, and, ultimately, preventing migraine progression and preserving brain health., EC has received honoraria from Novartis, Chiesi, Lundbeck, MedScape, Lilly, TEVA, Organon and Dr Reddy's; his salary has been partially funded by Río Hortega grant Acción Estratégica en Salud 2017–2020 from Instituto de Salud Carlos III (CM20/00217) and Juan Rodés fellowship, Subprograma Estatal de Incorporación de la Acción Estratégica en Salud 2023 (JR23/00065). He is a junior editor for Cephalalgia.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Optimizing Chronic Migraine Care: The Impact of Advanced Practice Nurse Involvement in OnabotulinumtoxinA Administration

  • Gine-Cipres, Eulalia
  • Gallardo López, Víctor J.
  • TORRES-FERRUS, MARTA
  • Alpuente Ruiz, Alicia
  • Caronna, Edoardo
  • Gómez Dabó, Laura
  • Pozo-Rosich, Patricia
Advanced practice nursing; Botulinum toxin type A; Headache, Infermeria de pràctica avançada; Toxina botulínica tipus A; Mal de cap, Enfermería de práctica avanzada; Toxina botulínica tipo A; Dolor de cabeza, Background: Chronic migraine is a disabling and prevalent neurological disease that significantly impacts patients' quality of life. OnabotulinumtoxinA (OnabotA) is a safe and effective chronic migraine preventive treatment. The objective was to evaluate adherence to the recommended time interval between consecutive OnabotA injections according to the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) protocol, and to analyze changes in the interval adherence before and after the introduction of an Advanced Practice Nurse (APN) in a specialized Headache Unit of a tertiary hospital. Methods: This was a retrospective study performed in a Spanish specialized Headache Clinic. Patients diagnosed with chronic migraine and treated with OnabotA following the PREEMPT protocol were included, before and after the introduction of APNs. Treatment was considered interval-compliant if the injection interval ranged from 75 to 105 days. The data collected included three 18-month periods. Statistical analyses examined differences across periods using R-Studio. Results: A total of 2991 participants were included, of whom 83.8% (2507/2991) were women, with a median age [interquartile range (IQR)] of 48.0 [40.0–57.0] years old. A statistically significant association between the introduction of the APN and improved adherence to the PREEMPT protocol was observed over time (Z = –19.60, p < 0.001). Adherence rates increased from 52.1% in P1 to 76.1% in both P2 and P3. The median time between visits decreased from 105 days in P1 to 96 days in P2, with a slight increase to 98 days in P3. Conclusion: The involvement of advanced practice nurses in OnabotA administration decreased the time interval between infiltrations and improved adherence to the PREEMPT protocol. These findings highlight the APN's role in optimizing patient care.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Neck pain in migraine: A narrative review and steps to correct evaluation and treatment

  • Rees, Tayla
  • Doukhi, Diana
  • Wang, Victor S
  • Balcerbula, Anita
  • Bravo, Michelle
  • fathi, haniyeh
  • Caronna, Edoardo
  • Pozo-Rosich, Patricia
Evaluation; Migraine; Neck pain, Avaluació; Migranya; Dolor cervical, Evaluación; Migraña; Dolor cervical, Background Neck pain is common in migraine patients, occurring during all migraine phases and between attacks. It can be a migraine symptom, trigger or a coexisting condition, and is associated with greater disability and poorer treatment response. There is evidence that neck pain associated with headaches can be frequently incorrectly diagnosed as a cervical disorder rather than migraine, resulting in a lack of appropriate treatment. Accurately assessing the connection between neck pain and migraine is crucial for effective treatment. Methods This narrative review aims to summarise existing research on the role and contribution of neck pain in migraine, both as a symptom and a trigger, and outlines future research needed to deepen our understanding of this relationship. It also proposes a structured approach for assessing neck pain in migraine and a treatment algorithm, offering guidance for clinical evaluation and treatment. For this purpose, a comprehensive narrative review was conducted using PubMed, covering preclinical, clinical, neurophysiological and imaging evidence on migraine and neck pain. Results Migraine patients frequently exhibit cervical dysfunction, tenderness and altered posture, with overlapping neuroanatomical pathways of the neck and trigeminal systems, suggesting shared mechanisms of nociception and migraine initiation. Clinical assessment involves a thorough history, physical exam and exclusion of secondary causes. Standard migraine therapies, such as amitriptyline and onabotulinumtoxinA, may help reduce neck pain and non-pharmacological treatments, such as physical therapy, acupuncture and behavioural strategies, show some promise. However, evidence on neck pain relief is limited. Conclusions Accurately distinguishing whether neck pain is a symptom, trigger or comorbid condition in migraine is essential for guiding effective treatment strategies. Both pharmacological and non-pharmacological approaches may help manage migraine-associated neck pain. However, few studies have assessed the effects of acute or preventive migraine therapies, particularly calcitonin gene-related peptide-targeted treatments, on neck pain, highlighting a significant gap in our current knowledge. Future research should evaluate the effectiveness of these therapies on neck pain, both alone and in combination with non-pharmacological interventions., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: TAR acknowledges receipt of the International Headache Society Fellowship from the International Headache Society. EC’s salary has been partially funded by Río Hortega grant Acción Estratégica en Salud 2017–2020 from Instituto de Salud Carlos III (CM20/00217) and Juan Rodés fellowship, Subprograma Estatal de Incorporación de la Acción Estratégica en Salud 2023 (JR23/00065).